C4 Therapeutics (CCCC) Equity Ratio (2019 - 2025)
C4 Therapeutics' Equity Ratio history spans 7 years, with the latest figure at 0.71 for Q4 2025.
- For Q4 2025, Equity Ratio rose 15.66% year-over-year to 0.71; the TTM value through Dec 2025 reached 0.71, up 15.66%, while the annual FY2025 figure was 0.71, 15.66% up from the prior year.
- Equity Ratio reached 0.71 in Q4 2025 per CCCC's latest filing, up from 0.58 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.79 in Q2 2021 to a low of 0.58 in Q3 2025.
- Average Equity Ratio over 5 years is 0.67, with a median of 0.66 recorded in 2023.
- Peak YoY movement for Equity Ratio: skyrocketed 215.37% in 2021, then fell 12.68% in 2022.
- A 5-year view of Equity Ratio shows it stood at 0.77 in 2021, then dropped by 12.68% to 0.67 in 2022, then fell by 2.61% to 0.65 in 2023, then decreased by 5.5% to 0.62 in 2024, then rose by 15.66% to 0.71 in 2025.
- Per Business Quant, the three most recent readings for CCCC's Equity Ratio are 0.71 (Q4 2025), 0.58 (Q3 2025), and 0.59 (Q2 2025).